Bio-Rad Laboratories, Inc. (BIO) Fair Value 2026

BIO · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

7.8 /10

32 fundamental signals · 11 models active

Value Trap Risk

SAFE (21/100)

Quick Summary — As of 2026-08-27, Bio-Rad Laboratories, Inc. (BIO) trades at $389.94, versus a $167.64 median fair value across its 11 active models — 57.0% below the current price. QOC: 7.8/10. Value Trap Risk: 21/100 (SAFE). 11/13 models active. Within that set, the Bayesian DCF component alone returns $283.45.

Key Facts

Ticker
BIO
Price
$389.94
Quality Score
7.8/10
Value Trap Risk
21/100
Models Active
11/13
Last Updated
Strength: 11 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

Is Bio-Rad Laboratories, Inc. (BIO) Undervalued or Overvalued in 2026?

According to CirclFi’s 11-model valuation engine, Bio-Rad Laboratories, Inc. (BIO) appears overvalued as of : the median of 11 independent fair value estimates is $167.64, 57.0% below the current price of $389.94. Estimates range from $62.62 to $327.35. BIO scores 7.8/10 on fundamental quality and 21/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. BIO’s -57.0% gap is wider than that market norm, and the Medical Devices sector median is -43.5%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Bio-Rad Laboratories, Inc. Stock in 2026? →

What Fair Value Does Each Model Give BIO?

11 Intrinsic Value Models vs. Current Price ($389.94)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $283.45 -27.3%
Intrinsic · High Conviction
 $104.97 -73.1%
Ensemble · Medium Conviction
 $167.64 -57.0%
Intrinsic · High Conviction
 $213.30 -45.3%
Unlock the Full Matrix

Access 7 additional models including Markov DDM, ML-RIV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 11 Models →

Cancel anytime · No contracts · Instant access

What Is BIO's Fair Value Range?

Spread across 11 independent models · $62.62 to $327.35

CirclFi's 11 active models place Bio-Rad Laboratories, Inc. (BIO) between $62.62 and $327.35 per share, a spread of 158% of the median. The median of that range — $167.64 — is the fair value CirclFi publishes for BIO, against a current price of $389.94.

Low · ML-RIVHigh · FTNN
$62.62median $167.64$327.35
Where the range comes from
Most bearish modelML Residual Income$62.62
Most bullish modelFTNN Topology$327.35
Model agreement0 bullish · 11 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for BIO. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on BIO, not a CirclFi price target. How each model works →

What Is Bio-Rad Laboratories, Inc. (BIO) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Bio-Rad Laboratories, Inc.'s intrinsic value is estimated at $167.64. Trading at its current price of $389.94, the valuation engine raises significant caution: 11 of 11 models flag downside risk, projecting a median implied return of -57.0%. Model dispersion is worth noting: FTNN targets $327.35 (-16.1%), versus ML-RIV at $62.62 (-83.9%). This +67.9% range highlights the importance of multi-model analysis rather than relying on any single methodology. Among models with highest confidence, Bayesian DCF, EPV lean bearish — adding weight to the bearish side of the thesis.

What Do the Models Say About BIO?

11 of 13 models are currently active for BIO. All 11 active models suggest the stock trades above fair value. Taken together, their median fair value for BIO is $167.64 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $283.45 on its own, implying -27.3% downside from the current price. See which stocks rank higher →

How Does BIO Rank in Medical Devices?

Among 157 Medical Devices stocks, BIO ranks #31 by Quality of Company score. CirclFi's QOC score of 7.8/10 evaluates 32 fundamental signals. A score of 7.8 indicates above-average quality.

See all Most Undervalued Medical Devices Stocks →

The Medical Devices sector introduces analytical considerations specific to biopharma enterprise businesses. For Bio-Rad Laboratories, Inc., metrics like pipeline depth and stage distribution provide important context that general-purpose valuation models may underweight.

Is BIO a Value Trap?

CirclFi's Value Trap algorithm assigns BIO a score of 21/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

11 of 13 models are active for Bio-Rad Laboratories, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Bio-Rad Laboratories, Inc. earns a quality score of 7.8/10. This robust rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

The gap between the most bullish and bearish model spans +67.9% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every BIO valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across BIO's 11 active models, average confidence is 52%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Bio-Rad Laboratories, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

MDTMedtronic plcQOC 7.8AXGNAxogen, Inc.QOC 7.6GEHCGE HealthCare Technologies Inc.QOC 7.9BRKRBruker CorporationQOC 7.5INFUInfuSystem Holdings, Inc.QOC 8.1SIBNSI-BONE, Inc.QOC 7.5CLPTClearPoint Neuro, Inc.QOC 6.5PLSMPulsenmore Ltd.QOC 5.6STMESTIMCELL ENERGETICS INC.QOC 3.7IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: MDT · AXGN · GEHC · BRKR · INFU · SIBN · CLPT · PLSM · STME · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to BIO?

7 companies across all industries closest to BIO’s Quality of Company score of 7.8/10.

ISTRInvestar Holding CorporationQOC 7.8RCKYRocky Brands, Inc.QOC 7.8AMKRAmkor Technology, Inc.QOC 7.8BANCBanc of California, Inc.QOC 7.8DOLEDole plcQOC 7.8BURLBurlington Stores, Inc.QOC 7.8NVDANVIDIA CorporationQOC 10.0

Read investment analysis: ISTR · RCKY · AMKR · BANC · DOLE · BURL · NVDA

Where Does BIO Sit in CirclFi's Medical Devices Rankings?

BIO is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About Bio-Rad Laboratories, Inc.’s Valuation?

What is Bio-Rad Laboratories, Inc.'s intrinsic value in 2026?

CirclFi puts Bio-Rad Laboratories, Inc. (BIO)'s intrinsic value at $167.64 — the median of 11 independent model estimates as of 2026-08-27, ranging from $62.62 to $327.35. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $283.45 on its own. The Quality of Company score is 7.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is BIO overvalued or undervalued right now?

At $389.94, 0 of 11 active models suggest BIO may be undervalued, while 11 indicate potential overvaluation. The median of all 11 fair value estimates is $167.64, 57.0% below the current price of $389.94 — a consensus view that BIO is overvalued. The assessment depends on which methodology best fits Bio-Rad Laboratories, Inc.'s business model in Medical Devices.

What does a Quality of Company score of 7.8 mean for BIO?

Bio-Rad Laboratories, Inc.'s QOC of 7.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on BIO?

CirclFi analyzes BIO with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 11 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on BIO?

Of the 11 models currently active on BIO, FTNN Topology is the most bullish at $327.35 per share, and ML Residual Income is the most bearish at $62.62. CirclFi's published fair value for BIO is the median of that range, $167.64, not either extreme. The gap between the two ends equals 158% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is BIO a value trap in 2026?

Bio-Rad Laboratories, Inc.'s Value Trap score is 21/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 11-model valuation engine, Bio-Rad Laboratories, Inc. (BIO) has a median fair value of $167.64 — 57.0% below the current price of $389.94 — as of 2026-08-27.” Source: circlfi.com/stock/BIO/ · Methodology
Primary sources for this BIO valuation
  • Financial statements: Bio-Rad Laboratories, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0000012208) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for BIO as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 11 mathematical frameworks give you clarity on BIO.

Unlock All 11 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

7 models hidden for BIO Unlock All 11 — $39/mo